Reported 22 days ago
AbbVie Inc. is positioned as a notable stock in the healthcare sector, projecting significant growth due to its robust product pipeline, particularly with popular medications like Skyrizi and Rinvoq. The company reported a revenue increase in fiscal Q4 2024, attributed to its new ex-Humira portfolio, with a commendable sales forecast. However, analysts also suggest that while AbbVie shows promise as an investment, AI stocks might deliver better returns within a shorter timeframe.
Source: YAHOO